Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest Update

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 805,900 shares, a growth of 8.7% from the February 13th total of 741,100 shares. Based on an average daily volume of 108,100 shares, the days-to-cover ratio is currently 7.5 days.

Alpine Immune Sciences Price Performance

Shares of ALPN stock opened at $8.04 on Thursday. Alpine Immune Sciences has a 12-month low of $4.82 and a 12-month high of $10.30. The firm has a market capitalization of $244.42 million, a price-to-earnings ratio of -4.49 and a beta of 1.29. The business has a 50 day simple moving average of $8.03 and a 200 day simple moving average of $7.20.

Hedge Funds Weigh In On Alpine Immune Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Decheng Capital Management III Cayman LLC boosted its stake in Alpine Immune Sciences by 42.5% during the 3rd quarter. Decheng Capital Management III Cayman LLC now owns 6,708,288 shares of the biotechnology company’s stock valued at $48,300,000 after purchasing an additional 2,000,000 shares in the last quarter. RA Capital Management L.P. boosted its stake in Alpine Immune Sciences by 0.9% during the 4th quarter. RA Capital Management L.P. now owns 4,397,368 shares of the biotechnology company’s stock valued at $32,321,000 after purchasing an additional 40,736 shares in the last quarter. Lynx1 Capital Management LP boosted its stake in Alpine Immune Sciences by 58.6% during the 3rd quarter. Lynx1 Capital Management LP now owns 3,056,420 shares of the biotechnology company’s stock valued at $22,006,000 after purchasing an additional 1,129,551 shares in the last quarter. Commodore Capital LP bought a new position in Alpine Immune Sciences during the 3rd quarter valued at $9,540,000. Finally, Vanguard Group Inc. boosted its stake in Alpine Immune Sciences by 78.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,122,800 shares of the biotechnology company’s stock valued at $8,084,000 after purchasing an additional 493,027 shares in the last quarter.

Analysts Set New Price Targets

ALPN has been the topic of a number of research reports. Morgan Stanley initiated coverage on Alpine Immune Sciences in a research report on Thursday, January 19th. They set an “overweight” rating and a $17.00 price target on the stock. SVB Leerink assumed coverage on Alpine Immune Sciences in a report on Monday, November 21st. They issued an “outperform” rating and a $15.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $15.80.

Alpine Immune Sciences Company Profile

(Get Rating)

Alpine Immune Sciences, Inc is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies.